Exclusive: Orakl Oncology raises $34m to test cancer drugs on ‘virtual patients’
AI-generated summary Orakl Oncology has secured $34 million in Series A funding to develop artificial intelligence virtual cancer patients. The Paris-based startup aims to test drugs and predict their effectiveness before clinical trials begin.